ESMO WCGIC 2021 | MATTERHORN: neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable G/GEJ

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, speaks on the MATTERHORN study (NCT04592913), a trial-in-progress assessing durvalumab and neoadjuvant FLOT chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery in patients with resectable gastric and gastroesophageal junction cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.